The most talked-about drug in a decade. Ozempic, Wegovy, and a wave of compounded copies have turned semaglutide into a cultural phenomenon. Here is what the research actually says — separated from the noise.
Semaglutide is a GLP-1 receptor agonist — a synthetic version of a hormone your body already makes called glucagon-like peptide-1 (GLP-1). Your gut releases natural GLP-1 after you eat. It tells your pancreas to release insulin, slows down gastric emptying (so food moves through your stomach more slowly), and signals your brain — specifically the hypothalamus — that you are full.
The drug was originally developed by Novo Nordisk for type 2 diabetes and approved as Ozempic (up to 1mg weekly injection) in 2017. Researchers noticed significant weight loss in diabetes patients, which led to the higher-dose formulation approved as Wegovy (2.4mg weekly) for chronic weight management in 2021.
Unlike natural GLP-1, which breaks down in minutes, semaglutide is engineered to last about a week in your body. It binds to albumin in the blood, which protects it from degradation and allows once-weekly dosing. This long half-life is what makes it practical — and also what means side effects can linger.
Semaglutide mimics a natural gut hormone. It does three things: makes your pancreas release more insulin (lowering blood sugar), slows your stomach emptying (so you feel full longer), and talks to the appetite center of your brain (so you want less food). The once-weekly formulation is engineered to last 7 days instead of minutes.
Social media, influencers, and compounding pharmacy marketing have created a mythology around semaglutide. Here are the most common claims you will encounter — and which ones hold up.
The STEP (Semaglutide Treatment Effect in People with obesity) trial program is the largest and most rigorous evidence base for semaglutide as a weight loss drug. These were randomized, double-blind, placebo-controlled trials — the gold standard.
These are real, impressive numbers. But context matters: the placebo group also received diet and exercise counseling and still lost only 2.4%. The drug clearly works. It is not, however, "no diet or exercise needed" — every STEP trial included lifestyle intervention as the baseline for both groups.
Semaglutide operates through multiple pathways simultaneously:
Binds the same receptors as your natural GLP-1 hormone, but resists enzymatic breakdown for ~7 days instead of minutes
Slows how quickly food leaves your stomach. This is why people feel full after small meals — and also why nausea is the most common side effect
Acts on appetite-regulating neurons in the brain. Patients consistently report reduced food noise — less thinking about food between meals
Enhances glucose-dependent insulin secretion and suppresses glucagon. Blood sugar improves before meaningful weight is lost
Gastrointestinal side effects are extremely common, especially during dose titration. From the STEP 1 trial data:
Most common. Usually worst in the first 4-8 weeks and during dose increases.
Typically mild to moderate. Can be persistent in some patients.
Often tied to eating too much or too quickly while on the drug.
About 7% of participants in STEP 1 discontinued treatment due to GI adverse events. Most side effects do improve with time and slow titration, but "no side effects" is flatly wrong. If you are considering semaglutide, plan for at least some GI disruption, particularly in the first two months.
This is arguably the most important nuance that gets buried in semaglutide hype. Rapid weight loss from any cause — caloric restriction, surgery, or GLP-1 drugs — involves losing both fat and lean mass.
DEXA body composition scans from STEP trials and follow-up analyses show that up to 40% of total weight lost can be lean mass (muscle, bone mineral content, organ tissue) in participants who did not do resistance training.
This is not unique to semaglutide — it happens with any rapid weight loss. But because semaglutide causes more weight loss than most interventions, the absolute amount of muscle lost can be substantial. For a person who loses 30 lbs, up to 12 lbs could be lean mass.
The mitigation is resistance training. Patients who combine semaglutide with consistent strength training retain significantly more lean mass. This should be a non-negotiable part of any semaglutide protocol, and it is rarely emphasized by prescribers or telehealth platforms.
The STEP 1 extension study (Rubino et al., 2021, JAMA) followed participants after they stopped semaglutide at 68 weeks:
Within 1 year of stopping, participants regained approximately two-thirds of the weight they had lost.
Cardiometabolic improvements (blood pressure, lipids, HbA1c) also partially reversed. This strongly suggests semaglutide is a chronic-use medication for most people — not a "course" you complete and then stop. The parallel to blood pressure or cholesterol medication is apt: the drug manages the condition while you take it.
The SELECT trial (Lincoff et al., 2023, NEJM) was a landmark study specifically designed to test cardiovascular outcomes:
SELECT is significant because it moves semaglutide from "weight loss drug" into "cardiovascular risk reduction" territory. This is why Wegovy received an expanded FDA indication for reducing cardiovascular events in adults with established CVD and overweight/obesity.
The surge in demand created a shortage of brand-name Wegovy and Ozempic, which opened the door for compounding pharmacies under FDA section 503A (individual prescriptions) and 503B (outsourcing facilities) to produce semaglutide.
Key things to understand:
Semaglutide is one of the most effective weight loss medications ever developed, with robust clinical trial data behind it. The ~15% average body weight reduction in STEP 1 is real and clinically meaningful. The cardiovascular benefits from SELECT add a second, independent reason to consider it.
But it is not magic. Nausea, vomiting, and diarrhea affect roughly half of users. Up to 40% of weight lost can be lean mass if you do not strength train. Most people regain two-thirds of the weight within a year of stopping. And compounded versions are a legal and quality gray zone.
The people who do best on semaglutide treat it as one part of a protocol — combined with resistance training, adequate protein intake, and careful tracking of their body composition, side effects, and metabolic markers. That is exactly what Dosi is built for.
Semaglutide for weight management (Wegovy) uses a slow titration schedule to minimize GI side effects. Each dose is maintained for 4 weeks before increasing. Your prescriber may adjust based on tolerability.
If you are on semaglutide, tracking the right data points separates people who get good outcomes from people who guess. Here is what matters:
Weekly, same time, same conditions. Track the trend line, not daily fluctuations.
Monthly DEXA or bioimpedance. This is how you catch lean mass loss early.
Log nausea, vomiting, diarrhea, constipation severity daily during titration. Pattern recognition matters.
Brief daily log. Some patients report fatigue or mood changes — data reveals patterns your memory won't.
Fasting glucose if you have a meter, or HbA1c at baseline and every 3 months. Tracks the metabolic benefit.
Every 3 months via lab work. The single best marker for long-term glucose control improvement.
Log location each week. Rotate systematically — belly, thigh, arm — to prevent tissue changes.
Not calorie counting — just note what changed. Reduced cravings, smaller portions, food aversions. This data is clinically useful.
Log doses, side effects, injection sites, and body composition. Let your data show you what is working — not someone else's anecdote.
Get Started Free →